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Replacement of myelin-forming cells is an attractive but unproven therapy for inherited and acquired myelin
diseases. In this issue ofCell StemCell, Windrem et al. (2008) describe the first progenitor cell transplantation
paradigm that rescues the neurological phenotypes and increases life spans of mice with inherited myelin
disease.Oligodendrocytes synthesize the insulat-
ing myelin membranes that increase the
speed of nerve conduction as much as
100-fold. Because destruction or malfor-
mation of myelin is a major cause of
human neurological disease, replacement
of myelin via transplantation of oligoden-
drocyte producing cells is a major focus
of central nervous system (CNS) regener-
ative medicine. Much is known about the
cellular and molecular aspects of oligo-
dendrogenesis and myelination. How-
ever, the field is far from reaching a
consensus on many critical aspects of
human treatment. Still debated are the
type and source of the donor cells, the tar-
get disease, the age of the recipient, the
mechanisms of cell delivery, and the sur-
rogate markers for tracking efficacy of
treatment. All of these decisions must be
given serious thought and be supported
by relevant and unequivocal animal stud-
ies. One adverse clinical advent could
substantially delay further development
of this promising therapeutic approach
for treating human diseases of myelin.
In this issue, Dr. Stephen Goldman’s
laboratory provides a compelling ‘‘proof-
of-principal’’ animal study that addresses
several critical issues facing the develop-
ment of future clinical trials in humans
(Windrem et al., 2008). In this study, hu-
man oligodendrocyte progenitor cells
(OPCs) were transplanted into the CNS
of newborn ‘‘shiverer’’ mice that lack my-
elin basic protein (MBP), a major protein
constituent of CNS myelin. Due to the
resulting dysmyelination, shiverer mice
typically develop truncal instability and
intention tremor and die by 5 months of
age (Chernoff, 1981). Dramatically, 4 of
26 transplanted shiverer mice survived
beyond a year, and their neurologicalphenotypes resolved. This manuscript is
the first to report rescue of neurological
phenotypes and increased life span in
mice with inheritedmyelin disease. There-
fore, infants with inherited and often fatal
myelin diseases provide an attractive
target population for human myelin repair
therapies using transplanted OPCs.
The purpose of cell-basedmyelin repair
strategies is to increase the number of
oligodendrocytes. When transplanted
into normal or pathological brains, these
differentiated cells have little capacity to
migrate or myelinate axons. Oligodendro-
cytes are produced by progenitor cells
that express a variety of surface markers
including the ganglioside A2B5, the sul-
fated proteoglycan NG2, and platelet-de-
rived growth factor receptor a (for review,
see Trapp et al., 2004). OPCs originate
from germinal zones lining the ventricles
and colonize the brain during early devel-
opment (Kessaris et al., 2006). This cell
type is the only known source of oligoden-
drocytes and represents a significant glial
cell population in the adult brain. Windrem
and colleagues isolated oligodendrocyte
progenitors from human fetal brain by
panning with A2B5 antibodies. Similar
selection techniques have been used to
obtain this population for decades, and
much is known about their behavior
in vivo, in vitro, and after transplantation
into animal models of myelin disease (for
review, see Baron-Van Evercooren and
Blakemore, 2004).
Several methodological differences
separate the Windrem study from previ-
ous approaches, notably the choice and
age of recipient animals, the cell delivery
approach, and the robust readouts of effi-
cacy of treatment. The therapeutic chal-
lenge in this model is for the transplantedCell Stemcells to migrate throughout the shiverer
brain, multiply, and give rise to oligoden-
drocytes that produce normal myelin
sheaths. This goal was attainted at un-
precedented levels, likely due to the high
density of OPCs that were injected at
five different sites. Human OPCs colo-
nized the white matter and differentiated
into oligodendrocytes, which myelinated
axons in the brain, cerebellum, brain
stem, and upper spinal cord. This myeli-
nation established normal nerve conduc-
tion velocities between the two brain
hemispheres and rescuedmost neurolog-
ical phenotypes in engrafted mice, includ-
ing the seizure activity and abnormal
respiration that are typically responsible
for the death of untreated shiverer mice.
The Windrem paper establishes that,
when transplanted into newborn brains,
human OPCs can respond to local devel-
opmental cues that regulate oligodendro-
cyte production and myelination. Most
importantly, the donor oligodendrocytes
can successfully compete with the defec-
tive host oligodendrocytes. Since most
human myelination occurs postnatally,
the microenvironment of the neonatal
brain is not significantly altered by dys-
myelination. This is relevant to the design
of human studies, because chronic dys-
myelination can cause astrocytic scars
that may inhibit OPC migration and oligo-
dendrocyte differentiation. In addition,
chronically dysmyelinated axons can be-
come dystrophic and degenerate. The
neonatal brain, therefore, appears to be
an appropriate host for cell-based myelin
repair strategies, andeffective therapeutic
intervention will likely require transplanta-
tion as soon as possible.
BecauseOPC transplantation improved
shiverer mouse survival and quality of life,Cell 2, June 2008 ª2008 Elsevier Inc. 519
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considered for human dysmyelinating dis-
eases. However, the parallels between
shiverer and man are not perfect. There
is no human equivalent of shiverer mice;
however, mutations in other myelin pro-
teins do cause severe dysmyelination
and neurological disability in humans.
For example, Pelizaeus-Merzbacher Dis-
ease (PMD) is caused by genetic defects
in proteolipid protein (PLP), the most
abundant protein in CNS myelin. Various
PLP mutations cause a wide range of
clinical phenotypes that reflect the sever-
ity of the dysmyelination (reviewed by
Hudson et al., 2004). A subgroup of PMD
infants exhibits markedly abnormal white
matter MRI signals at birth. Their poor
prognosis provides a reasonable risk/ben-
efit assessment to become candidates for
cell transplantation therapy. Success of
OPC transplantation into these connatal
forms of PMD could be noninvasively
monitored by brain imaging. It remains
possible, however, that human neurons
also express PLP isoforms and thus could
be directly impacted by PLP mutations
(Miller et al., 2003). If this is the case, res-
cuing the dysmyelination will not rescue
the neurodegeneration. Despite these
concerns, connatal PMD appears the
most appropriate target for human OPC
transplantation therapy at the present
time.
Additional due diligence must be ad-
dressed prior to initiating human trials. It
is important to note that only a minority
of the shiverer mice (4 of 26) were rescued520 Cell Stem Cell 2, June 2008 ª2008 Elsevby neonatal OPC transplantation. Was the
limited success due to injection failure, as
suggested by the authors, or because of
variation in the quality of the donor human
cells?While this topic received little atten-
tion in the Windrem paper, the use of hu-
man fetuses as a source of OPCs will be
an issue for future human trials for a variety
of reasons. In addition to questions re-
garding ethical procurement and use of
fetal tissues, not to mention the chal-
lenges related to obtaining sufficient cell
numbers, potential immunogenicity of
the transplanted population must also be
considered. Although the mammalian
CNS is often considered immune privi-
leged, adverse immune events have
been described in individuals receiving
bone marrow transplants to treat a variety
of CNS diseases. The Windrem paper
skirted this issue by transplanting OPCs
into shiverer mice that were rendered
immunodeficient by crossing them to
the Rag2-deficient background. Immune-
competent rodent-rodent transplants
would better mirror future human trials
and would address whether transplanted
cells will evoke a CNS immune response
and whether immunosuppressive therapy
would be a needed and tolerable adjunct.
Another challenge is whether successful
application of the technique to the larger
human brain will require more cells, more
injection sites, or both. These issues could
be addressed in part by transplanting
OPCs into the shaking pup, an inherited
dysmyelinating canine model (Nadon
et al., 1990).ier Inc.The application of cell transplantation
therapies to treat human diseases of my-
elin is likely to be undertaken in the next
few years. It is critical to the field of myelin
repair that the odds for success are max-
imized and supported by unequivocal
animal studies. In this context, Windrem
and colleagues provide a compelling
case for transplantation of human OPCs
into infants with inherited and often fatal
defects in myelination.
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